JP2016501185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501185A5 JP2016501185A5 JP2015541885A JP2015541885A JP2016501185A5 JP 2016501185 A5 JP2016501185 A5 JP 2016501185A5 JP 2015541885 A JP2015541885 A JP 2015541885A JP 2015541885 A JP2015541885 A JP 2015541885A JP 2016501185 A5 JP2016501185 A5 JP 2016501185A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently hydrogen
- membered
- heteroatoms selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
- 150000001721 carbon Chemical group 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- -1 or N Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723827P | 2012-11-08 | 2012-11-08 | |
| US61/723,827 | 2012-11-08 | ||
| PCT/US2013/068866 WO2014074670A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501185A JP2016501185A (ja) | 2016-01-18 |
| JP2016501185A5 true JP2016501185A5 (enrdf_load_stackoverflow) | 2016-11-24 |
| JP6266639B2 JP6266639B2 (ja) | 2018-01-24 |
Family
ID=49667570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541885A Active JP6266639B2 (ja) | 2012-11-08 | 2013-11-07 | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮαの調節に有用なアルキルアミド置換ピリミジン化合物 |
Country Status (14)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181937T1 (hr) | 2012-11-08 | 2019-01-25 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklični spojevi korisni kao modulatori il-12,il-23 i/ili ifn-alfa |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2018081488A1 (en) * | 2016-10-28 | 2018-05-03 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| CN107857754B (zh) * | 2018-01-15 | 2018-11-09 | 泰山医学院 | 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用 |
| JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ２媒介性シグナル伝達の阻害剤 |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| AU2019443366A1 (en) * | 2019-04-30 | 2021-12-02 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| TW202246233A (zh) | 2021-02-19 | 2022-12-01 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| BR112023016590A2 (pt) | 2021-02-19 | 2023-11-14 | Sudo Biosciences Ltd | Inibidores de tyk2 e seus usos |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| KR20050019797A (ko) * | 2002-06-28 | 2005-03-03 | 야마노우치세이야쿠 가부시키가이샤 | 디아미노피리미딘카르복사미드 유도체 |
| WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
| RU2410379C2 (ru) * | 2004-09-30 | 2011-01-27 | Тиботек Фармасьютикалз Лтд. | 5-замещенные пиримидины, ингибирующие вич |
| JP5095409B2 (ja) * | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ， インコーポレイテッド | スピロ２，４−ピリミジンジアミン化合物およびその使用 |
| WO2007113254A1 (en) * | 2006-03-30 | 2007-10-11 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-amido substituted pyrimidines |
| US20100010025A1 (en) * | 2006-07-21 | 2010-01-14 | Norvartis Ag | Pyrimidine Derivatives |
| JP5802127B2 (ja) * | 2008-04-16 | 2015-10-28 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋ又はｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド類 |
| JP5705720B2 (ja) * | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| AR076550A1 (es) * | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
| EP2440204B1 (en) * | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| WO2012145569A1 (en) | 2011-04-22 | 2012-10-26 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| HRP20181937T1 (hr) | 2012-11-08 | 2019-01-25 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklični spojevi korisni kao modulatori il-12,il-23 i/ili ifn-alfa |
| KR102233252B1 (ko) | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
-
2013
- 2013-11-07 US US14/441,213 patent/US9540333B2/en active Active
- 2013-11-07 EA EA201590911A patent/EA028052B1/ru not_active IP Right Cessation
- 2013-11-07 CN CN201380069688.2A patent/CN104903301B/zh active Active
- 2013-11-07 JP JP2015541885A patent/JP6266639B2/ja active Active
- 2013-11-07 AU AU2013341195A patent/AU2013341195B2/en not_active Ceased
- 2013-11-07 CA CA2890935A patent/CA2890935A1/en not_active Abandoned
- 2013-11-07 EP EP13795913.6A patent/EP2917186B1/en active Active
- 2013-11-07 WO PCT/US2013/068866 patent/WO2014074670A1/en not_active Ceased
- 2013-11-07 KR KR1020157011660A patent/KR102205914B1/ko active Active
- 2013-11-07 BR BR112015009798A patent/BR112015009798A2/pt not_active Application Discontinuation
- 2013-11-07 SG SG11201503395TA patent/SG11201503395TA/en unknown
- 2013-11-07 ES ES13795913.6T patent/ES2648226T3/es active Active
- 2013-11-07 MX MX2015005561A patent/MX2015005561A/es unknown
-
2015
- 2015-05-04 IL IL238605A patent/IL238605A/en not_active IP Right Cessation